Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Effekter av urolithin A-tilskudd på glukosemetabolisme hos friske voksne 55 >= år gamle: en randomisert trippelmasket kontrollert klinisk studie

18. november 2026 oppdatert av: National Institute on Aging (NIA)

Effektene av Urolithin A-tilskudd på glukosemetabolisme hos friske voksne >= 55 år. En randomisert trippelmasket kontrollert klinisk studie

Background:

As people age, the cells in the pancreas that produce insulin begin to release less of this hormone, and levels of blood glucose (sugar) rise. This can lead to illnesses such as diabetes. Urolithin A (UA) is a natural nutritional supplement that may improve how the body controls blood glucose.

Objective:

To learn if UA improves levels of insulin and other hormones that help control blood glucose.

Eligibility:

People aged 55 years and older with a body mass index of 27 or higher.

Design:

Participants will have 6 clinic visits over 8 weeks.

Participants will be screened. They will have a physical exam with blood and urine tests and a test of their heart function.

UA gelcaps are taken by mouth every morning at home. Half of participants will take UA. The other half will take a placebo. The placebo looks like the study drug but does not contain any medicine. Participants will not know which they are taking.

Participants will have tests during the study including:

Oral glucose tolerance: Participants will drink a sweet liquid. Blood will be drawn at intervals over the next 3 hours.

Continuous glucose monitor: A sensor with a needle that goes just under the skin will be placed on the upper arm. Participants will wear this sensor throughout the study.

Exercise. Participants will walk on a treadmill while their heart rate, hearth rhythm, and blood pressure are monitored. They will walk in a hallway at normal and fast paces.

Imaging scans of the thigh; scans of the brain are optional....

Studieoversikt

Status

Rekruttering

Forhold

Detaljert beskrivelse

Study Description:

We hypothesize that supplementation with the nutritional supplement urolithin A (UA) in healthy adults >= 55 years old will; (i) increase insulin secretion by boosting beta cell metabolism of glucose, resulting in increased ATP generation as pyruvate enters the TCA cycle after glycolysis, thereby enhancing early, acute insulin secretion and glucose uptake in skeletal muscle -both of which will lower circulating levels of blood glucose, (ii) boost production and secretion of incretin hormones because their secretion is also dependent on cellular depolarization, (iii) boost mitochondrial function in brain and muscle tissues. (iv) alter gut microbiome. These effects will be examined over an 8-week period. The study will include a Screening Visit and 5 additional study visits.

Objectives:

Primary Objective:

To determine if UA supplementation will increase the rate at which beta cells respond to glucose.

Secondary Objectives:

Investigate if UA alters incretin secretion in response to oral glucose (incretins are secreted only in response to nutrients) and uncover if UA increases brain and skeletal muscle metabolism.

Endpoints:

Primary Endpoint:

To determine if urolithin A supplementation will influence insulin secretion in response to oral glucose at 4 and 8 weeks after supplementation.

Secondary Endpoints:

  • To determine if UA supplementation will increase incretin secretion in response to oral glucose at 4 and 8 weeks after the supplementation.
  • To determine if UA supplementation will enhance mitochondria respiration, based on p31 spectroscopy by thigh MRI/MRS at baseline and 8 weeks after supplementation.
  • To determine if UA will increase brain oxidative metabolism, based on brain MRS at baseline and 8 weeks after supplementation.
  • To determine if UA supplementation will alter gut microbiome composition.
  • To determine if Uroltihin A supplementation alters the percentage of immune cell types.

Studietype

Intervensjonell

Registrering (Antatt)

180

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studer Kontakt Backup

Studiesteder

    • Maryland
      • Baltimore, Maryland, Forente stater, 21224
        • Rekruttering
        • National Institute of Aging, Clinical Research Unit
        • Ta kontakt med:

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

55 år til 100 år (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

  • INCLUSION CRITERIA:

In order to be eligible to participate in this study, an individual must meet all of the following criteria:

  • Provision of signed and dated informed consent form.
  • Stated willingness to comply with all study procedures and availably for the duration of the study.
  • Male or female, age >= 55 years.
  • Able to speak and read English. (We do not have ready access to interpreters of different languages at the NIA Clinical Unit).
  • BMI >= 27.
  • Ability to take oral medication and be willing to adhere to the daily regimen.
  • Ability to perform walking and treadmill tests without physical limitations.
  • In good general health, as evidenced by medical history/physical exam/laboratory results.

EXCLUSION CRITERIA:

An individual who meets any of the following criteria will be excluded from participation in this study:

  • History of diabetes requiring treatment with any glucose lowering drug(s).
  • Fasting glucose >= 126 on screening visit.
  • Is on treatment with an investigational drug or other intervention within 8 weeks of enrollment.
  • Hospitalization within 12 months for myocardial infarction, coronary revascularization or bypass surgery or stroke.
  • History of autoimmune disease, e.g., Hashimoto s thyroiditis, Myasthenia Gravis or Rheumatoid Arthritis.
  • Uncontrolled thyroid disease.
  • Chronic liver disease indicated by medical history or one of the liver enzymes greater than 2 times the normal range.
  • History of chronic kidney disease or GFR <60 mL/min/1.73 m^2.
  • Anemia (defined as hemoglobin level <12 g/dl for men or < 11 g/dl for women).
  • Poor venous access.
  • Uncontrolled hypertension as judged by the Investigator.
  • History of significant GI disease, e.g., IBS, Crohn s disease.
  • Active cancer or has had treatment for cancer in the last 1 year.
  • Medical condition requiring absolute and continuous need for long-term treatment with antibiotics, corticosteroids, immunosuppressors.
  • Currently pregnant or a nursing mother due to possible changes in hormones and metabolism.
  • History of, or laboratory evidence of HIV virus infection at Screening Visit.
  • History of, or laboratory evidence of Hepatitis B or C at Screening Visit.
  • Positive urine drug screen at Screening Visit (unless taking prescribed medication and at the discretion of the PI).
  • Reports claustrophobia and/or is not eligible to have an MRI as per the MRI eligibility form.
  • Weight >= 300 lbs (MRI scanner weight limit).
  • Hip or knee replacement or other medical condition that prevents MRI research scans from being performed.
  • Diagnosed with cognitive impairment that clearly prevents the participant from providing informed consent.
  • Current smoker or tobacco use in the past year.
  • History of substance abuse, including marijuana use in the past year.
  • On average, consumes more than 1 alcoholic drink per day.
  • Any other condition which in the investigator s opinion may adversely affect the subject s ability to complete the study or its measures or which may pose significant risk to the subject.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Grunnvitenskap
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Firemannsrom

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Placebo komparator: Placebo

50% of participants

The placebo will consist of methylcellulose and will appear identical to the active supplement. The placebo will be provided by the manufacturer of Urolithin A.

Aktiv komparator: Urolithin A

50% of participants

Urolithin A (UA) is a widely available dietary supplement devoid of any known sided effects that is reported to improve mitochondrial function. The UA substance used in this investigation is regulated under Generally Recognized as Safe (GRAS) by the US FDA (GRN No. 000791) (https://www.fda.gov/media/120300/download) and is being advertised and sold as an oral supplement. The daily dose (1 gram) and duration (8 weeks) have already been tested in previous clinical trials.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
To determine if urolithin A supplementation will influence insulin secretion in response to oral glucose at 4 and 8 weeks after supplementation.
Tidsramme: 8 weeks

Study visits 1 - 5

8 weeks

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
To determine if UA supplementation will increase incretin secretion in response to oral glucose at 4 and 8 weeks after the supplementation.
Tidsramme: 8 weeks

Study visits 1 - 5

8 weeks
To determine if UA supplementation will enhance mitochondria respiration, based on p31 spectroscopy by thigh MRI/MRS at baseline and 8 weeks after supplementation.
Tidsramme: 8 weeks

Study visits 1 &amp; 5

8 weeks
To determine if UA will increase brain oxidative metabolism, based on brain MRS at baseline and 8 weeks after supplementation.
Tidsramme: 8 weeks

Study visits 1 &amp; 5

8 weeks
To determine if UA supplementation will alter gut microbiome composition.
Tidsramme: 8 weeks

Study visits 1, 3 &amp; 5

8 weeks

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Hovedetterforsker: Josephine M Egan, M.D., National Institute on Aging (NIA)

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Antatt)

24. november 2026

Primær fullføring (Antatt)

31. mars 2027

Studiet fullført (Antatt)

31. mars 2027

Datoer for studieregistrering

Først innsendt

22. februar 2024

Først innsendt som oppfylte QC-kriteriene

22. februar 2024

Først lagt ut (Faktiske)

23. februar 2024

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

19. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

18. november 2026

Sist bekreftet

17. juli 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere